Generic Challenge:. Martin a. Voet

record, during recent years, the generic drug companies have adopted a “take no prisoners” attitude and are challenging virtually all new drug patents at the earliest possible time. Branded pharmaceutical companies today have virtually all of their current products under attack by generics.

      One of the main reasons for the on-going consolidation of the pharmaceutical industry is the shortening of product life-cycles caused by generics entering the market at earlier times in the product life-cycle. As the innovative product life-cycle gets shorter, simple economics suggests that the pharmaceutical industry must recover its long term investment over the shorter time period. This inevitably results in higher drug prices, which leads to further political pressures for Canadian re-importation of lower priced drugs, price controls, excise taxes on new drugs, etc.

      Under such conditions, it would not be wise to take the survival of the innovative pharmaceutical industry for granted. An interesting example of this is the drug policy in Canada which has now come full circle.

      The Canadian government decided many years ago that it preferred to reimburse inexpensive generic drugs to more costly innovative branded drugs and established governmental policies to achieve that. There was no data protection in Canada for drug dossiers and the only thing preventing a new pharmaceutical product becoming generic almost from day one was a patent. Even there the law was not very friendly to innovators and it was the policy of the health authorities and even the courts to officially favor the generic industry.

      The net result was that there is virtually no innovative drug industry in Canada and like Blanche in A Street Car Named Desire; it depends on the kindness of strangers for future innovative drugs. Interestingly, because of price controls for branded drugs, innovative drugs are cheaper in Canada than in the U.S., but generic drugs are more expensive. If all countries took Canada’s approach, eventually, there would be no innovative pharmaceutical industry and no new innovative drugs.

      To Canada’s credit it has now recognized the negative aspects of its drug policy and has implemented new regulations to provide for up to eight years of regulatory exclusivity for new drugs approved after June 17, 2006. This will encourage innovation by insuring a minimum of eight years of exclusivity for a new drug before it can be made available in Canada as a generic drug. Further details on the new Canadian drug rules can be found in Chapters 5 and 6.

      The purpose of this book is to familiarize the reader with both the strategic and tactical aspects of enhancing pharmaceutical product life-cycles utilizing a variety of interactive tools including patents and regulatory exclusivities, together with an understanding of applicable laws including the Hatch Waxman Act for conventional generic drugs and the corresponding Biologics Price Competition and Innovation Act (BPCIA) for biologic generics or so-called biosimilars.

      However, this is not as easy as it may sound. Patent law tends to be an arcane specialty with its own jargon like “prior art”, “terminal disclaimer” and “102 reference”; while FDA law, with its dense and almost impossible to understand regulations and its own jargon like “505(b)(2) filing” and “Phase III clinical trial”, is not much better.

      The following Dilbert carton does a pretty good job of illustrating how many people think about patents: somehow important, but at the same time not very understandable.

      DILBERT © 2012 Scott Adams. Used By permission of UNIVERSAL UCLICK. All rights reserved.

      Furthermore, when you need an answer to a patent question, you ask a patent lawyer. If the question also involves FDA regulatory issues, you will generally be told that that is an area outside the expertise of the patent lawyer and you should consult an expert in FDA law or regulation. So you find such a person and they will tell you all you need to know about FDA law and regulations, but if the question also involves patents in any significant way, they will tell you it is outside their area of expertise, so please to consult a patent lawyer.

      This Catch 22 problem for pharmaceutical managers and executives is that there are an increasing number of important “you bet your product” issues that depend on fully understanding how patent and regulatory laws and regulations and statutes such as the Hatch Waxman Act interact to influence the long-term success of a pharmaceutical product.

      That means pharmaceutical managers and executives alike who want to succeed in their jobs have no choice but to become knowledgeable in these matters, so that they can plan for the successful development and long term success of their company’s pharmaceutical products. This book might also be helpful to the regulatory lawyer or patent lawyer (who can save time by skipping the chapter on his or her specialty) who wishes he or she had a better understanding of the interaction of patent law with regulatory law so that they can better see the bigger picture and help achieve the goal of successful pharmaceutical product lifecycle management.

      This book is intended to explain those subjects in understandable language so that you, the reader, will be able to ask the right questions and understand the answers you receive. Keep in mind this book is not intended to be, nor could it be, a substitute for competent counsel in patent law and FDA regulatory matters, nor is it a substitute for expert consultants in pharmaceutical product life-cycle management.

      The first three chapters are on patents. Chapter 1 is an Overview of Patents. Chapter 2 covers Patent Enforcement and Infringement and Chapter 3 describes Pharmaceutical, Biologic and Medical Device Patents. These chapters provide the necessary basic background in patents for understanding pharmaceutical product life-cycle management. The next two chapters relate to regulatory matters. Chapter 4 is an Overview of FDA and Chapter 5 covers Exclusivity for Brand Name Innovative Drug Products. These chapters provide the basics for understanding how FDA regulations and brand name product exclusivities affect product life-cycle management. Chapters 6 and 7 discuss the final pieces of the puzzle. For conventional generic drugs: Generic Drugs: Hatch Waxman Act; and for biologic generics: Generics for Biologic Drugs, covering the Biologics Price Competition and Innovation Act of 2009 (BPCIA), which for the first time authorizes generics (or “biosimilars”) for biologically produced branded drugs in the United States. Then Chapter 8 synthesizes the previous seven chapters in Putting it All Together: Product Life-Cycle Management. Finally Chapter 9 closes with some Conclusions and Final Thoughts.

Chapter

1

      Overview of Patents

      The invention all admired,

      and each, how he

      To be the inventor missed,

      so easy it seemed

      Once found, which yet unfound

      most would have

      thought impossible.

      John Milton

      Paradise Lost

      “Genius is one percent inspiration and

      ninety-nine percent perspiration.”

      Thomas A. Edison

ORIGINS OF U.S. PATENTS

      Patents have been around longer than you may think. Article I, Section 8 of the U.S. constitution provides that

      “Congress shall have the Power … to promote the Progress of Science and Useful Arts by securing for limited Times to Authors and Inventors the exclusive Right to their respective Writings and Discoveries.”